Project Grant R01CA288850
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$553K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $530,697 to The Trustees of the University of Pennsylvania to conduct research on the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The overarching objective is to systematically explore the dynamic changes in the regulome induced by PRMT inhibitor treatments in these cancer...
This $112,052 federal project grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by the University of Pennsylvania to overcome treatment resistance in gynecological cancers. The key objectives are:
Develop new therapies that exploit genetic vulnerabilities in gynecological cancers with CCNE1 amplification, which are platinum-resistant with poor outcomes. This includes testing drug combinations and identifying biomarkers that...
The National Cancer Institute (NCI) awarded a $1,373,308 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to conduct research on metabolic mechanisms contributing to chemoresistance in high-grade serous ovarian carcinoma (HGSOC). The research aims to quantitatively map the role of acetylcarnitine-dependent histone acetylation in promoting homologous recombination-mediated DNA repair, and to investigate whether suppressing intracellular acetylcarnitine...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) totaling $101,458 provides funding to the University of Washington to conduct research aimed at improving the understanding and treatment of triple negative breast cancer (TNBC). The key objectives are to:
Retrospectively identify tumor habitat signatures from multiparametric MRI scans to stratify TNBC patients and predict treatment outcomes (Aim 1); and
Prospectively employ...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to assess the role of the DCAF15 protein in acute myeloid leukemia (AML). The primary objectives are to: (A) decipher the biological function of DCAF15 in myeloid development and leukemia in vivo, (B) investigate the role of cohesin acetylation in AML pathogenesis, and (C) develop small molecule degraders targeting DCAF15. The award of $483,760 was granted to The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...
This $698,008 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by The Trustees of the University of Pennsylvania to investigate the relationship between branched-chain amino acid metabolism and histone propionylation, a chromatin modification associated with gene expression, in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanisms by which nuclear-localized branched-chain...
This federal Project Grant award, totaling $719,799.00, was provided by the National Cancer Institute (NCI) under its Cancer Biology Research program (CFDA 93.396). The grant aims to investigate the impact of metabolic adaptations on the tumor microenvironment and immune response in metastatic triple-negative breast cancer (TNBC). Key objectives include:
Examining the bifunctional mechanisms by which the metabolic enzyme PFKFB4 regulates TNBC tumor cell plasticity and metastatic competence...
This $241,944 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research into the pharmacological potential of combined translation and autophagy inhibition for treating high-grade serous ovarian cancer (HGSOC). The research aims to study the efficacy and mechanism of action of two natural product compounds, didesmethylrocaglamide (DDR) and phyllanthusmin34 (PHY34), as a...